174 related articles for article (PubMed ID: 36036471)
1. Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients.
Ju C; Lian Q; Chen A; Zhao B; Zhou S; Cai Y; Xie H; Wei L; Li S; He J
Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36036471
[TBL] [Abstract][Full Text] [Related]
2. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
3. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia.
Tu S; Zhang K; Wang N; Chu J; Yang L; Xie Z
Sci Rep; 2023 Nov; 13(1):18789. PubMed ID: 37914820
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
Tang L; Yang XF; Qiao M; Zhang L; Tang XW; Qiu HY; Wu DP; Sun AN
J Mycol Med; 2018 Jun; 28(2):379-383. PubMed ID: 29673771
[TBL] [Abstract][Full Text] [Related]
6. Why do lung transplant patients discontinue triazole prophylaxis?
Pennington KM; Razonable RR; Peters S; Scott JP; Wylam M; Daly RC; Kennedy CC
Transpl Infect Dis; 2019 Jun; 21(3):e13067. PubMed ID: 30866168
[TBL] [Abstract][Full Text] [Related]
7. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole liquid vs tablet formulation in lung transplant recipients.
Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
[TBL] [Abstract][Full Text] [Related]
10. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
11. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
[TBL] [Abstract][Full Text] [Related]
12. Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study.
Chen X; Wang J; Wang S; Jin J; Li J; Gao S; Li J; Li J; Liu Q; Hu Y; Lin D; Sun Z; Yang J; Hu J; Wu X; Huang X; Shao Z; Deng Q; Wang C; Liu L; Chen H; Wang J; Wei X; Shen J; Zhang X; Wu D
Medicine (Baltimore); 2021 Jul; 100(30):e26772. PubMed ID: 34397725
[TBL] [Abstract][Full Text] [Related]
13. A pharmacokinetic analysis of posaconazole oral suspension in the serum and alveolar compartment of lung transplant recipients.
Thakuria L; Packwood K; Firouzi A; Rogers P; Soresi S; Habibi-Parker K; Lyster H; Zych B; Garcia-Saez D; Mohite P; Patil N; Sabashnikov A; Capoccia M; Chibvuri M; Lamba H; Tate H; Carby M; Simon A; Leaver N; Reed A
Int J Antimicrob Agents; 2016 Jan; 47(1):69-76. PubMed ID: 26607341
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study.
Ye P; Pei R; Hu Y; Chen D; Li S; Cao J; Li F; Wu M; Fang Y; Lu Y
BMC Infect Dis; 2022 May; 22(1):465. PubMed ID: 35570276
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience.
Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Ivulich S; Neoh CF; Slavin MA; Kong DCM
J Antimicrob Chemother; 2017 Jul; 72(7):2089-2092. PubMed ID: 28369489
[TBL] [Abstract][Full Text] [Related]
16. Comparing posaconazole and itraconazole for antifungal prophylaxis in critically ill lung transplant recipients: Efficacy and plasma concentrations.
Kallee S; Scharf C; Schroeder I; Paal M; Vogeser M; Irlbeck M; Zander J; Zoller M; Jung J; Kneidinger N; Schneider C; Michel S; Liebchen U
Transpl Infect Dis; 2021 Aug; 23(4):e13675. PubMed ID: 34166573
[TBL] [Abstract][Full Text] [Related]
17. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
18. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
[TBL] [Abstract][Full Text] [Related]
19. Low dose posaconazole delayed release tablets for fungal prophylaxis in lung transplant recipients.
Kozuch JM; Feist A; Yung G; Awdishu L; Hays S; Singer JP; Florez R
Clin Transplant; 2018 Aug; 32(8):e13300. PubMed ID: 29806967
[TBL] [Abstract][Full Text] [Related]
20. Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals.
Heimann SM; Penack O; Heinz WJ; Rachow T; Egerer G; Kessel J; Claßen AY; Vehreschild JJ
Int J Infect Dis; 2019 Jun; 83():130-138. PubMed ID: 30978465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
